Teva Income Tax Expense from 2010 to 2024

TEVA Stock  USD 22.09  0.78  3.66%   
Teva Pharma's Income Tax Expense is decreasing over the years with stable fluctuation. Overall, Income Tax Expense is projected to go to about -61.8 M this year. From 2010 to 2024 Teva Pharma Income Tax Expense quarterly data regression line had arithmetic mean of (95,296,667) and significance of  0.46. View All Fundamentals
 
Income Tax Expense  
First Reported
1992-03-31
Previous Quarter
630 M
Current Value
69 M
Quarterly Volatility
220.6 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Teva Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Teva Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 B, Interest Expense of 1.1 B or Total Revenue of 9.5 B, as well as many indicators such as Price To Sales Ratio of 0.7, Dividend Yield of 0.0042 or PTB Ratio of 1.48. Teva financial statements analysis is a perfect complement when working with Teva Pharma Valuation or Volatility modules.
  
Check out the analysis of Teva Pharma Correlation against competitors.

Latest Teva Pharma's Income Tax Expense Growth Pattern

Below is the plot of the Income Tax Expense of Teva Pharma Industries over the last few years. It is Teva Pharma's Income Tax Expense historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Teva Pharma's overall financial position and show how it may be relating to other accounts over time.
Income Tax Expense10 Years Trend
Pretty Stable
   Income Tax Expense   
       Timeline  

Teva Income Tax Expense Regression Statistics

Arithmetic Mean(95,296,667)
Coefficient Of Variation(643.38)
Mean Deviation370,296,000
Median(61,750,000)
Standard Deviation613,121,774
Sample Variance375918.3T
Range2.6B
R-Value(0.21)
Mean Square Error387570.6T
R-Squared0.04
Significance0.46
Slope(28,311,964)
Total Sum of Squares5262856.3T

Teva Income Tax Expense History

2024-61.8 M
2023-65 M
2022-638 M
2021211 M
2020-168 M
2019-278 M
2018-195 M

About Teva Pharma Financial Statements

Teva Pharma stakeholders use historical fundamental indicators, such as Teva Pharma's Income Tax Expense, to determine how well the company is positioned to perform in the future. Although Teva Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Teva Pharma's assets and liabilities are reflected in the revenues and expenses on Teva Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Teva Pharma Industries. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Income Tax Expense-65 M-61.8 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Teva Pharma Industries offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Teva Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Teva Pharma Industries Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Teva Pharma Industries Stock:
Check out the analysis of Teva Pharma Correlation against competitors.
You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teva Pharma. If investors know Teva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teva Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.4
Earnings Share
(0.85)
Revenue Per Share
14.879
Quarterly Revenue Growth
0.125
Return On Assets
0.0556
The market value of Teva Pharma Industries is measured differently than its book value, which is the value of Teva that is recorded on the company's balance sheet. Investors also form their own opinion of Teva Pharma's value that differs from its market value or its book value, called intrinsic value, which is Teva Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teva Pharma's market value can be influenced by many factors that don't directly affect Teva Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Teva Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teva Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.